Levels of vascular endothelial growth factor and pigment epithelium-derived factor in eyes before and after intravitreal injection of bevacizumab

[1] Adamis A.P.(1994)Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy Am J Ophthalmol 118 445-450

[2] Miller J.W.(1994)Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders N Engl J Med 331 1480-1487

[3] Bernal M.T.(1994)Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy Arch Ophthalmol 112 1476-1482

[4] Aiello L.P.(1996)Inhibition of vascular endothelial growth factor prevents retinal ischemia associated iris neovascularization in a nonhuman primate Arch Ophthalmol 114 66-71

[5] Avery R.L.(1995)Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins Proc Natl Acad Sci U S A 92 10457-10461

[6] Arrigg P.G.(2005)Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration Ophthalmic Surg Lasers Imaging 36 331-335

[7] Malecaze F.(2006)Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration Ophthalmology 113 363-372

[8] Clamens S.(2005)Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion Ophthalmic Surg Lasers Imaging 36 336-339

[9] Simorre-Pinatel V.(2006)Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) Retina 26 352-354

[10] Adamis A.P.(2006)Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study) Retina 26 1006-1013

[1] Adamis A.P.(1994)Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy Am J Ophthalmol 118 445-450

[2] Miller J.W.(1994)Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders N Engl J Med 331 1480-1487

[3] Bernal M.T.(1994)Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy Arch Ophthalmol 112 1476-1482

[4] Aiello L.P.(1996)Inhibition of vascular endothelial growth factor prevents retinal ischemia associated iris neovascularization in a nonhuman primate Arch Ophthalmol 114 66-71

[5] Avery R.L.(1995)Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins Proc Natl Acad Sci U S A 92 10457-10461

[6] Arrigg P.G.(2005)Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration Ophthalmic Surg Lasers Imaging 36 331-335

[7] Malecaze F.(2006)Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration Ophthalmology 113 363-372

[8] Clamens S.(2005)Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion Ophthalmic Surg Lasers Imaging 36 336-339

[9] Simorre-Pinatel V.(2006)Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) Retina 26 352-354

[10] Adamis A.P.(2006)Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study) Retina 26 1006-1013